Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh(National Cancer Center Hospital East), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Miyako Satouchi(Hyogo Prefectural Cancer Center), Makoto Nishio(Japanese Foundation For Cancer Research), Noboru Yamamoto, Haruyasu Murakami(Shizuoka Cancer Center), Naoyuki Nogami(Shikoku Cancer Center), Shingo Matsumoto(National Cancer Center Hospital East), Takashi Kohno, Koji Tsuta(Kansai Medical University), Katsuya Tsuchihara(National Cancer Center Hospital East), Genichiro Ishii(National Cancer Center Hospital East), Shogo Nomura(National Cancer Center Hospital East), Akihiro Sato(National Cancer Center Hospital East), Atsushi Ohtsu(National Cancer Center Hospital East), Yuichiro Ohe, Kōichi Goto(National Cancer Center Hospital East)
Cited by 295
Abstract
Related Papers
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al.|New England Journal of Medicine|2004|11.5k